PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65738-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)65738-5/fulltext
Title :
PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65738-5&doi=10.1016/S1098-3015(10)65738-5
First page :
Section Title :
Open access? :
No
Section Order :
104